News Hub | News Direct

XRP (XRP), BNB (BNB), and KangaMoon (KANG) Continue Their Stellar Performance With Holder Excitement Increasing - Here’s Why

Kangamoon

Recently, XRP (XRP), BNB (BNB), and KangaMoon (KANG) have experienced tremendous growth. Thus fueling the crypto community’s sense of hope. While XRP and BNB are already-established cryptos, KANG is a Stage 2 presale star that could evolve into the next 100x meme coin in 2024. Keep reading to find out why. Ali Martinez Makes a Bullish XRP Price Prediction XRP (XRP) has been on a tear lately. As per CoinMarketCap data, the XRP price has jumped from $0.50 to $0.59 in the past 30 days. Its market cap also increased from $27B to $32B during that time. Crypto analyst Ali Martinez claims that this bullish trend may continue. In his tweet, Martinez predicts this crypto will surge to $0.65 soon. From a technical analysis perspective, the future looks bright for the XRP crypto. In other words, over 22 technical indicators are flashing green for it. Additionally, XRP now trades above its 100 and 200-day EMAs. Due to all these reasons, analysts predict that XRP will reach a value of $0.81 within Q2 of 2024. BNB (BNB): Breaches the $400 Barrier Meanwhile, BNB (BNB) has also seen tremendous growth. The BNB price has surged from $302 to $407 in the last month alone. These are levels not seen since April 2022. The BNB market cap pumped from $45B to $60B in that period. According to More Crypto Online’s new YouTube video, this crypto may grow to $597 soon. BNB is now trading above its 100 and 200-day EMAs. Furthermore, this crypto has experienced 18/30 (60%) green trading days. All these factors have caused experts in the crypto field to make a bullish BNB price prediction. They forecast a potential jump to $526 for the BNB crypto within Q2 of 2024. KangaMoon (KANG): A Meme Coin Surging by 50% KangaMoon (KANG) is making a name for itself in the meme coin space, and it’s doing so at an alarming rate. The presale has raised nearly $500K. People are interested in this one-of-a-kind meme coin. KANG will have actual utility, unlike 99% of meme coins currently available. KANG will be used as in-game currency on KangaMoon’s upcoming P2E game. Players will use this meme coin to upgrade their characters or purchase in-game items. Not only that, KANG holders gain access to exclusive challenges that will run on a weekly/monthly and quarterly basis. By winning these challenges, you earn extra tokens and in-game items. KANG stands out because you can win tokens during its presale just by sharing posts on social media. This fusion of Play-to-Earn (P2E) and Social-Fi elements could generate the most active meme community. In Stage 2 of its presale, this meme coin costs merely $0.0075. Those who bought it early are enjoying a 50% ROI. However, remember that KangaMoon will enter the P2E NFT games market, which Yahoo Finance valued at $329M in 2022. Thus, its future looks bright, and experts predict a 100x pump once KANG hits exchanges in Q2 of 2024. Will KangaMoon Stand Out From XRP and BNB? With a low market cap of $7.5M, KangaMoon positions itself for rapid growth. To clarify, KANG requires fewer new funds to propel its price to higher levels. Therefore, KANG stands out from XRP and BNB and emerges as one of the top meme coins to watch. If interested, follow the links below for a 10% bonus on each purchase. Discover the Exciting Opportunities of the KangaMoon (KANG) Presale Today! Website: https://Kangamoon.com/ Integrating GameFi and Play To EarnEmbark on your quest for glory. Assemble your champions, engage in epic battles or bet on your favorite fighters to earn $KANG tokens and exclusive rewards. Gain control of rare NFTs, unlock exclusive content and build alliances with fellow gamers as you ascend the ranks and leaderboards. Disclaimer: The following disclaimer is important to read and understand before engaging with Kangamoon, a play-to-earn meme coin. By accessing or participating in any activities related to Kangamoon, you acknowledge and accept the terms outlined below: 1 No Financial Advice: The whitepaper and any associated content do not constitute financial advice, investment recommendations, or solicitation to purchase Kangamoon tokens. The information provided is for informational purposes only. It is your responsibility to conduct thorough research and seek professional advice before making any financial decisions. 2 Volatility and Risks: Cryptocurrencies, including Kangamoon, are volatile and subject to significant price fluctuations. Investing in or holding Kangamoon tokens involves substantial risks, including the possibility of total loss. Past performance is not indicative of future results. 3 Regulatory Compliance: The regulatory environment surrounding cryptocurrencies is evolving and varies across jurisdictions. It is your responsibility to ensure compliance with applicable laws and regulations in your country or region before engaging with Kangamoon. 4 Uncertain Market: The market for meme coins and play-to-earn platforms is highly speculative and subject to rapid changes. There is no guarantee of market demand, liquidity, or utility for Kangamoon tokens. Token values may fluctuate drastically and may not reflect the intrinsic value of the project. By continuing to engage with Kangamoon, you acknowledge and accept the risks and limitations outlined in this disclaimer. You should only participate if you fully understand and are willing to assume these risks. Contact Details Kangamoon marketing@kangamoon.com Company Website https://kangamoon.com/

March 04, 2024 09:00 AM Central Standard Time

Image

Forte Minerals Acquires the Alto Ruri Epithermal Gold Prospect Near Barrick’s Pierina Mine in Central Perú

Forte Minerals Corp.

Forte Minerals Corp. ( “ Forte ” or the “ Company ” ) ( CSE: CUAU ) ( OTQB: FOMNF ) ( Frankfurt: 2OA ), has finalized the acquisition of the Alto Ruri high sulphidation epithermal gold (“ Au ”) prospect and the Cerro Quillo porphyry Au-copper (“ Cu ”)-molybdenum (“ Mo ”) prospect from its strategic partner Globetrotters Resource Group Inc. (“ GlobeTrotters ”). Both are situated on a contiguous 4700 ha block of concessions that were initially acquired by Globetrotters from Compañía Minera Ares S.A.C. (“ Ares ”) in exchange for a 1.0% NSR royalty interest. These concessions were transferred to Forte’s Peruvian subsidiary, Cordillera Resources Perú S.A.C., in exchange for a one-time cash payment of US$25,000. The Alto Ruri prospect was drill tested by Compañía de Minas Buenaventura (“ Buenaventura ”) in 1997 who completed a two-stage, 12-hole drill program that included eight (8) NQ core and a four (4) reverse circulation (“ RC ”) drill holes totalling 2254.5 m. GlobeTrotters’ then subsidiary Rio Marañon Minerals S.A.C. (“ Rio Marañon ”) re-analysed portions of the core from the eight (8) diamond drill holes in 2011 with hole 001-97 returning significant Au values averaging 2.55 g/t Au over 131 m starting from surface, including 54 m of 5.39 g/t Au 1 (Tables 1 and 2). The Au mineralization is associated with the vuggy silica replacement of quartz-clay altered volcanoclastic rocks typical of high sulphidation epithermal Au alteration (Figure 2) but true widths are unknown. Table 1: Assay results from diamond drill hole 001-97 at Alto Ruri. The Cerro Quillo prospect was drill tested by Anglo American Exploration Perú S.A. in 2004 who completed a nine (9) hole RC drill program for a total of 2684.90 m. The holes were drilled in the vicinity of the Cerro Quillo Porphyry Complex located three (3) km to the west of Alto Ruri. The historical assay results from hole 003-Q returning 200 m of 0.49 g/t Au, 0.09% Cu, and 0.007% Mo but true widths are unknown (Table 2). The Cerro Quillo Porphyry Complex is a series of mineralized diorite porphyry dikes intruding Miocene aged intermediate to felsic volcanic and volcanoclastic rocks. The system is potassic altered with secondary biotite alteration, A-type and B-type veins, and local magnetite stringers overprinted by a larger 2.5 km x 1.5 km phyllic-argillic alteration zone comprised of pervasive sericite-clay alteration, D-type veins and locally disseminated tourmaline. Table 2: Reported drill hole collar information (WGS84 Zone 18S). The original source of the historical assay results in RC drill hole 003-Q is from a 2011 technical report prepared by Rio Marañon. The information suggests that porphyry Au-Cu-Mo mineralization may be present in this area. The rock chip and geochemical sample reject materials from 003-Q are no longer available for re-assaying purposes. For that reasons, the historical Au assay results from RC drill hole 003-Q have not been verified by the Company. The Project is located just 15 km due south of the Pierina Au Mine (“ Pierina ”) owned by Barrick Gold Corp in central Perú which has produced over 8 million ounces (“ Oz ”) of Au since commercial production in 1999 (Figure 1). As with Pierina, these prospects are situated along the Cordillera Negra and associated with Miocene aged volcanic and volcanoclastic rocks forming part of the Tertiary Volcanic Arc which is known to host several large Miocene aged epithermal Au deposits including Newmont’s (Minas Buenaventura-Sumitomo) Yanacocha and Minas Congas deposits as well as several large Miocene aged porphyry Cu-Mo-(+Au) deposits including Chinalco’s Toromocho, Southern Copper’s Michiquillay and Rio Tinto’s (First Quantum Minerals) La Granja deposits. Patrick Elliott, President, and CEO, remarked, "This acquisition is a strategic win for Forte, thanks to the decade-long persistence and determination of our partner, Globetrotters, in securing these prospects. Both lie in the highly prospective Tertiary Volcanic Arc of north-central Peru. This region actively hosts some of South America's largest epithermal Au and porphyry Cu-Mo-Au deposits. Adding these assets to our portfolio enhances our copper and gold asset base. It significantly mitigates the risks associated with the early stages of exploration and discovery in a premier mining jurisdiction." Exploration Manager, Manuel Montoya comments, “ Both the Alto Ruri and Cerro Quillo prospects exhibit large zones of intense hydrothermal alteration and mineralization similar to other large Miocene aged epithermal Au and porphyry Cu-Mo-Au deposits that occur in this prolific mineral belt. The results from the historical drilling on both prospects were very encouraging with significant Au values returned over sizeable widths. We are excited to hopefully continue advancing this project with further drilling.” Additionally, as GlobeTrotters is the beneficial owner of more than 10% of Forte’s outstanding shares, it is a “related party” to the Company within the meaning of Multilateral Instrument 61-101- Protection of Minority Security Holders in Special Transactions ("MI 61-101"). As such, the acquisition of the Alto Ruri prospect and the Cerro Quillo prospect constitutes a "related party transaction" within the meaning of MI 61-101. The Company has relied on exemptions from formal valuation and the minority shareholder approval requirements of MI 61-101 found in sections 5.5(a) and 5.7(1)(a) of MI 61-101 as the fair market value of the transaction does not constitute more than the 25% of the Company’s market capitalization. QUALIFIED PERSON and NI 43-101 DISCLOSURE Richard Osmond, P.Geo., is the Company’s Qualified Person (“ Qualified Person ”) as defined by National Instrument 43-101 and has reviewed and approved the technical information contained in this news release. REFERENCE TO HISTORICAL DATA The data disclosed in this news release is related to historical drilling results. Forte has not undertaken any independent investigation of the sampling, nor has it independently analyzed the results of the historical exploration work in order to verify the results. Forte considers these historical drill results relevant as the Company considers this data to be a significant indication of the exploration potential of the Alto Ruri and Cerro Quillo prospects. Any future exploration work by the Company's will include the verification of the historical data through drilling. Rio Marañon supervised the historical geochemical sampling of portions of the drill core from the eight (8) diamond drill holes completed by Buenaventura at Alto Ruri. The core was logged and sampled by Rio Marañon at a secure storage facility located 27 km to the southeast of Lima, Perú where the core is currently stored. The individual core samples collected for analysis ranged in length from 0.5 m to 10.20 m averaging of 1.94 m and where previously sampled by Buenaventura, the core was quarter cut using a rotary diamond blade saw. The samples were then sealed at the storage facility and transported to ALS Peru S.A.C. (“ ALS ”) an independent analytical laboratory in Lima. ALS analyzed the samples by fire assay on a 30-gram sample with an AAS finish (Au-AA23). Where the Au-AA23 analysis returned greater than 10 ppm Au, a 30-gram split was reanalysed by fire assay fusion with a gravimetric finish (Au-GRA21). In addition to ALS laboratory protocols, Rio Marañon employed an internal QA/QC program that included the insertion of reference standards (source unknown) on site and is not aware of any drilling, sampling, recovery, or other factors that could have materially affected the accuracy or reliability of the data reported. The Qualified Person has reviewed the technical data and the original assay certificate provided by ALS and has verified these results. ABOUT FORTE MINERALS CORP Forte Minerals Corp., a junior exploration company that has blended assets in partnership with GlobeTrotters Resources Perú S.A.C., has built a robust portfolio of high-quality Cu and Au assets in Perú. The Company aims to generate significant value growth by strategically situating early-stage and drill-ready targets alongside a historically discovered and drilled porphyry system for Cu and Au resource development. Notwithstanding its resource focus, Forte is deeply committed to community engagement, environmental stewardship, and fulfilling its societal responsibilities. On behalf of FORTE MINERALS CORP. (signed) “ Patrick Elliott” Chief Executive Officer For further information, please contact: Forte Minerals Corp. office: 604-983-8847 info@forteminerals.co m www.forteminerals.com Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements and information reflect management's current beliefs and are based on assumptions made by and information currently available to the company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under "Risk Factors and Uncertainties" in the Company's latest management’s discussion and analysis, which is available under the Company's SEDAR+ profile at www.sedarplus.ca, and in other filings that the Company has made and may make with applicable securities authorities in the future.. Forward-looking statements are not a guarantee of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements. Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Contact Details Patrick Elliott, President & CEO +1 604-983-8847 info@forteminerals.com Company Website https://forteminerals.com/

March 04, 2024 05:55 AM Pacific Standard Time

Image

MicroSalt revolutionises salt intake with low sodium technology and big growth plans

MicroSalt PLC

MicroSalt PLC (AIM: SALT) CEO Rick Guiney tells Proactive's Stephen Gunnion that the recently listed company specialises in innovative food technology that enhances the flavour of salt with significantly less sodium through patented technology. This technology changes the salt crystal's size, increasing its surface area for a fuller flavour without excess sodium intake, a major global health concern. The company targets food manufacturers, offering a product with the same functionality as traditional salt but processed differently. Additionally, MicroSalt aims to enter consumer markets, with products already available on Amazon in the UK and in about 500 stores in the US. MicroSalt's technology is distinguished by an exclusive patent, marking a significant advancement in efforts to reduce sodium consumption over the past two decades. The company's strategy includes expanding into the UK retail market, engaging with major supermarket groups to offer MicroSalt on shelves and incorporate it into their own brands, aiming for products like crisps to retain their taste while having 50% less sodium. The decision to list on the AIM market reflects London's receptivity to small food technology firms and its strategic importance in the food and ingredients sector. MicroSalt's IPO aims to raise public awareness about its low-sodium solution and the broader health issues related to sodium intake. Regulatory support for low sodium initiatives is significant, with governments recognizing the health and economic benefits of reducing sodium consumption. MicroSalt has also announced an export collaboration with American Trading International (ATI), facilitating access to 90 markets through ATI's distribution network, and enhancing the company's growth prospects. Looking ahead, MicroSalt anticipates significant developments in 2024 and 2025 as it expands its reach to consumers and large food manufacturers. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

March 04, 2024 08:47 AM Eastern Standard Time

Video

News Release

Voyageur Pharmaceuticals and API Forge Alliance for Carbon-Based Imaging Drug Advancement

Voyageur Pharmaceuticals Ltd.

Calgary, Canada – TheNewswire - March 4, 2024 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the "Corporation") and Applied Pharmaceutical Innovation (API), a leading industry-funded not-for-profit organization driving life sciences commercialization, proudly announce the signing of a Master Services Agreement ( MSA ). This collaboration represents a significant advancement in both entities’ commitment to innovation, heralding a transformative step forward for Canada’s thriving life sciences sector. Under this strategic agreement, API will play a crucial role in accelerating Voyageur’s imaging contrast medium product development, manufacturing, and commercialization. Leveraging API’s scientific and pharmaceutical expertise, the collaboration aims to facilitate regulatory approvals and expedite the market entry of Voyageur’s contrast imaging products. This partnership will strategically target FDA, Health Canada and other regulatory agencies, by licensing across several key development areas: Accelerating the development and registration of the innovative V@C60 MRI drug (Vanadium Fullerene Molecule for magnetic resonance imaging https://voyageurpharmaceuticals.ca/voyageur-pharmaceuticals-ltd-and-rain-cage-carbon-inc-announce-breakthrough-in-imaging-technology-with-vanadium-fullerene-molecule/ Developing novel fullerene imaging products for targeted drug delivery within the body, with a focus on applications in Oncology. Introducing an advanced suite of new barium contrast media products, with the goal to displace current products in the market. Expanding Voyageur’s Iodine contrast media product pipeline, including potential development of fullerene iodine products Developing a carbon 60 based nutraceutical health supplement "We are thrilled to embark on this groundbreaking collaboration with Voyageur, advancing healthcare through the commercialization of mineral-based active pharmaceutical ingredients for the medical imaging market," stated Andrew MacIsaac, CEO at API. "This partnership underscores our commitment to driving innovation and elevating the life sciences landscape in Canada and globally." Brent Willis, CEO of Voyageur, expressed excitement about the collaboration, stating, "Our vision is to become the world's first company capable of creating new carbon-based drugs from captured CO 2, ensuring carbon-neutral pharmaceuticals. This strategic alliance with API will accelerate Voyageur's development programs, with a primary focus on creating a groundbreaking carbon-based MRI drug and advancing our iodine contrast media product pipeline." By amalgamating API's regulatory expertise with Voyageur's research and development capabilities, this partnership is poised to showcase global leadership in pharmaceutical development. The collaboration exemplifies how the intersection of Alberta's strengths in natural resources, scientific innovation, and environmental stewardship can result in enhanced healthcare solutions worldwide. Together, API and Voyageur aim to streamline the integration of Voyageur’s contrast media products, reducing supply chain risks and aiding healthcare practitioners in diagnosing diseases, disorders, and abnormalities globally. About Voyageur Pharmaceuticals Ltd.: Voyageur (TSX Venture Exchange: VM) is a Canadian public company at the forefront of barium, iodine, and carbon Active Pharmaceutical Ingredients (API) and high-performance, cost-effective imaging contrast agents. Focused on vertically integrating the barium, iodine, and carbon contrast imaging market, Voyageur aims to become a key player by producing its own minerals. Committed to sustainability, Voyageur envisions a future of carbon neutrality. Utilising Rain Cage Carbon Inc patented Eden System, Voyageur plans to capture carbon producing an added revenue stream to help finance operations and create the carbon used for new drug development. The Corporation holds a 100% interest in the Frances Creek property, a NI-43-101 barium sulfate (barite) project with an assigned $344M NPV based on a 2021 preliminary economic assessment. Voyageur is building vertical integrated product lines that are all 100% carbon neutral. About API: API stands as one of Canada's largest life sciences commercialization organizations, dedicated to enhancing the quality-of-life sciences. As an industry-funded not-for-profit, API provides end-to-end support to life sciences researchers, businesses, and innovators on their journey from idea to commercialization. With scientific leadership from Nobel Laureate Sir Michael Houghton, API provides access to facilities and experts that help pharmaceutical projects reach the market. With a commitment to sharing expertise, resources, and infrastructure, API aims to build an unparalleled life sciences sector driving prosperity for all. For media inquiries, please contact: Voyageur Pharmaceuticals Ltd. API (Applied Pharmaceutical Innovation) Tessa Vriend, Director, Engagement & Brand tessa.vriend@appliedpharma.ca Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Cautionary Statement Regarding “Forward-Looking” Information. This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to the perceived benefits to Voyageur from entering into the MSA; Voyageur’s expectations and timing with respect to developing pharmaceutical drugs including the Va@C60 MRI drug, fullerene imaging drugs, new barium contrast drugs, iodine contrast and fullerene iodine drugs, and nutraceutical health supplements; Voyageur’s perceived costs and other benefits from its collaboration with API; Voyageur’s anticipated plans and benefits from its relationship with API; Voyageur’s expectation that it will be able to secure the financing necessary to pursue its objectives; and other statements herein, which expressly or impliedly speak to Voyageur’s expectations for its business and operations. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties, including, without limitation, global market factors and supply chain issues, risks relating to the regulation and approval of Voyageur’s products, and general risks relating to Voyageur’s business. There can be no assurance that such information will prove to be accurate and actual.

March 04, 2024 08:30 AM Eastern Standard Time

Knightscope (NASDAQ: KSCP) Demonstrates The Value In Its Autonomous Security Robots As Clients Continue To Renew Recurring Revenue Contracts

Benzinga

By Faith Ashmore, Benzinga Robots are taking over headlines in 2024 as the world continues to advance and companies around the globe showcase innovative ways to incorporate robots into our society. The robotics market was valued at $31.38 billion in 2021 and is expected to reach $110.39 billion by 2030, with a CAGR of 15% from 2022-2030. One company that is demonstrating how robotics can be integral to public safety is Knightscope (NASDAQ: KSCP), a technology company ushering in the dawn of Autonomous Security Robots (ASRs). Knightscope’s success has garnered attention across the nation, and the company has won corporate contracts with major corporations, law enforcement agencies and even the U.S. Federal Government. These clients are among a long list of other collaborations. However, one of the most impressive aspects of these partnerships is how many continue to re-sign with Knightscope – the company reports that several re-sign for 3, 4, 5, 6, 7 and even 8 consecutive years. This is a key proof point in the company’s claim of “recurring revenue for the recurring societal problem of crime.” In February, the company announced the renewal of its K5 ASR contract with a long-standing client in the entertainment industry. This renewal marks the eighth consecutive year of collaboration between the client – who is based in North Hollywood – and Knightscope. Knightscope reports that the client has consistently expressed satisfaction with the ASRs' ability to deter security threats, making it a top priority in their quarterly business reviews. Before the deployment of the ASRs, the client faced issues such as trespassing, vandalism, theft and break-ins. However, over the past seven years, these incidents have been significantly reduced to only a few isolated cases. A Las Vegas apartment complex has also recently renewed its contract for the K5 ASR for the fourth consecutive year. The success of this deployment was previously covered by the Las Vegas Review-Journal and News 3 Las Vegas, highlighting the company's ability to maintain a dedicated customer base, reduce acquisition expenses and provide cost-efficient solutions in order to positively impact its financial outlook. Starting from February 28, 2024, Knightscope will be participating in multiple events throughout Las Vegas. The first one is the World Game Protection Conference at the Tropicana. On March 18, 2024, EVP and Chief Client Officer Stacy Stephens will return to Mandalay Bay for Shoptalk. Stephens will be a panelist for the session titled “Enhancing Store Performance, Security and Safety.” Another event in April is also in the pipeline and will be announced at a later date. Contract renewals are not just routine procedures; they exemplify Knightscope's capacity to foster growth, stability and strengthened partnerships with existing clients. In January, a Fortune 500 company located in Charlotte, NC renewed its contract with Knightscope for a third year. Since 2022, the finance company has chosen to utilize the K5 ASR for patrolling a recently built parking structure. These ongoing renewals not only validate the company's Machine-as-a-Service (MaaS) business model but also generate recurring revenue that contributes towards solving a persistent societal issue. While the company is always looking for new business, consistent and recurring partnerships serve to highlight trust and satisfaction in Knightscope's products and business model. These renewals also provide valuable opportunities to nurture relationships and better understand evolving client needs, as well as the potential for recommendations or the expansion of business opportunities – all while reducing costs and making the world safer. Click here to read more about the company’s future plans from CEO William Santana Li Featured photo courtesy of Knightscope. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AVAILABLE HERE. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

March 04, 2024 08:30 AM Eastern Standard Time

Image

No More Jitters? Company Says Its Hydro-CaffeineTM Improves Your Morning Caffeine Fix’s Benefits By 400-500%

Rexis Biotech

By Meg Flippin, Benzinga It’s no secret that many people turn to chugging caffeine-induced drinks to get them through the day. But what they may not realize is too much caffeine can be a bad thing. Jitters, elevated heart rates and anxiety are just some of the side effects many consumers just learn to accept. But caffeine overload doesn’t have to be the foregone conclusion just to get your caffeine fix. Products like Rexis Biotech Inc.’s Hydro-Caffeine TM are revolutionizing the energy drink market. Thanks to its nanotechnology, the Delaware biotech firm says it has created a better caffeine that gives you energy without all the bad side effects. Quadruple The Effects For Less Hydro-Caffeine can be found in Rexis’s new groundbreaking energy drink Squared Energy, a product line extension to their already successful Squared brand which is available in over 2,000+ retailers in 10 states across the country. It is created using the company’s proprietary co-crystal that amplifies the effects by increasing the bioavailability of its caffeine co-crystal by four to five times. Rexis is taking it up a level with this drink by fusing Hydro-Caffeine with naturally occurring Hemp Delta-9 THC + broad-spectrum CBD to create a singular polymorph molecule in which all three work together for the ultimate entourage effect. That creates a unique experience for consumers highlighted by clear-headed, focused energy without any jitters or anxiety, according to Rexis. The first two flavors they’ll be bringing to market include a Raspberry Lemonade and their High Spirits Awards-winning Sparkling Grapefruit. Hydro-Caffeine could be a huge winner for both consumers and Rexis shareholders; caffeine is a very popular energy stimulant. Not only does caffeine give you energy but it can reduce the risk of cardiovascular disease and type 2 diabetes and improve longevity, which is why caffeine is so popular in the U.S. and abroad. While coffee and tea are the most common ways to get a caffeine fix, energy drinks, caffeine pills and supplements are also popular. In fact, the global energy drinks market is poised to reach $108.4 billion by 2031, growing at a CAGR of 8.2% from 2022 to 2031. In the U.S. 93% of Americans say they consume caffeine, with 75% partaking in it daily, according to the International Food Information Council. One-quarter of that group consumes caffeine three or more times a day. It is the latter group that worries doctors. Caffeine overdose is real and can lead to several issues including insomnia, jitters, anxiety, elevated heart rate and headaches. It tends to happen a lot since many Americans underestimate the safe amount of caffeine to consume and still remain healthy. Worse, the International Food Information Council found nearly 29% of consumers in the U.S. say they don’t know what the safe amount of caffeine is. The Secret Sauce Rexis says that with Squared Energy, you need not worry about getting too much or too little caffeine to reap the benefits. The secret behind it is the Hydro-Caffeine fibers which are absorbed more efficiently and rapidly through sublingual and buccal absorption in the cheeks and mouth. That differs from traditional energy drinks, which use a form of encapsulated caffeine in which the caffeine is coated with a sugar-type substance to eliminate bitter flavors. That process increases the time it takes to absorb, decreasing the portion introduced into circulation. The caffeine then must be processed by first-pass metabolism, which reduces efficacy even more. As a result, Rexis says you may receive as much as 25% less of the ingredient in your system than what is said on the packaging. “Shaking Up” The Market Rexis’s potentially game-changing Squared Energy drink isn’t the only way the biotech is shaking up the consumer markets. With its proprietary nanotechnology, it can improve the potency, taste and speed of effectiveness in everything from energy drinks to cannabis-infused beverages. The goal of Rexis Biotech is to be the Nvidia Corp. (NASDAQ: NVDA) or Intel Corp. (NASDAQ: INTC) of the consumer packaged goods industry. It envisions a world where brands license Rexis’s nanotechnology to enhance everything from drinks to food. To meet that end Rexis also manufactures and distributes products for companies including Hemp D9 beverages for 3Chi and functional mushrooms for First Person. It also licenses its technology to brands in the regulated cannabis market including Smokiez and Happy Valley. Caffeine will always be a preferred way to get a boost, but that doesn’t mean consumers have to accept the negative side effects. Jitters, headaches and elevated heart rates could become a thing of the past thanks to Rexis Biotech. Rexis Biotech is currently raising funds to support its growth. Click here to learn more about Rexis Biotech’s crowdfunding raise, and how to invest in the company the founders are modeling after Nvidia! Featured photo by Mark Daynes on Unsplash. Rexis is the industry leader and pioneer in developing Hydrophobic Molecule Delivery systems. Leading in the innovation, production and formulation of water based ingredients for use in the Pharmaceutical and Consumer Packaged goods industry. Established in 2022, Rexis is building a core mix of proprietary IP used to sustain strong sales models with pharmaceutical licensees, consumer packaged goods manufacturers and clinical research teams. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Ryan Erving ryan@rexissystems.com Company Website https://www.rexissystems.com

March 04, 2024 08:25 AM Eastern Standard Time

Image

News Release

Enhanced Design Breakthrough Makes Ventripoint's VMS+ Even Simpler to Use

Ventripoint Diagnostics Ltd.

***Faster, User Friendly Cardio AI Imaging Product for Commercial Roll Out*** Toronto, Ont. — TheNewswire --- March 04, 2024 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT ); ( OTC:VPTDF) released a significant upgrade to the design and function of its whole-heart analysis system (VMS+3.2), which accelerates imaging, analysis and ease of use at the point of care. The new design allows immediate calibration by technicians with existing ultrasound equipment to more quickly generate 2D ultrasound images, which the VMS+3.2 turns into a high-definition 3D heart model. The upgraded system also includes an improved 3D visualization tool, which speeds up and facilitates the analysis of 3D ultrasound exams. VMS+3.2 release improves the ease-of-use of 2D and 3D echocardiogram procedures for sonographers, cardiologists and caregivers, assuring seamless integration of Ventripoint technology into patient-care workflow and standard of care. In a busy echocardiography unit, reducing the time for a procedure without compromising the quality of the results is a constant challenge and the VMS+3.2 will be appreciated for these innovations. “We are constantly improving the design of our system, to generate efficiencies and better outcomes,” said Ventripoint’s Interim CEO, Hugh MacNaught. “This is a best-in-class diagnostic tool that allows enhanced echocardiograms of infants and adults to be available faster and at less cost than a cardiac MRI, with equivalent structural and functional results.” The new design removes the magnet from the probe-tracking system and so it is now immune to environments where magnetic fields are present and is no longer a concern for implanted patient medical devices, such as pacemakers and other cardiac devices, where magnets can be disruptive. The Company intends to submit to regulatory agencies for the removal of this limitation on the VMS+ system. Ventripoint’s technology is now being used in leading hospitals in Europe, the UK, Canada, China and the United States as an alternative to traditional MRI heart scans. These users will be offered the VMS+3.2 upgrade for a fee and future sales will be of the VMS+3.2 version. The Company is now focused on expanding the user base in hospitals and clinics worldwide. The Company has a world-class board of clinical advisors who continue to provide ideas for design improvements, which are ongoing. The company expects to announce additional enhancements in 2024, which will require regulatory approvals and enable VMS+ to be used with a wider range of patients. It is important to note that these future upgrades are software improvements, which can be seamlessly integrated into existing and new VMS+ units. For further information, please contact: Jonathan Robinson CFA JRobinson@oakhillfinancial.ca (416) 669-1001 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. About Ventripoint Diagnostics Ltd. Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada. Forward Looking Statements This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.

March 04, 2024 08:22 AM Eastern Standard Time

BestGrowthStocks.Com Issues Comprehensive Analysis of Marpai Inc

Marpai

NEW YORK, NY / NewsDirect / March 4th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis of Marpai Inc. a health-tech company that uses AI and data to maximize healthcare outcomes. Marpai Inc (NASDAQ: MRAI) AI-based business model to lower costs while providing better healthcare options for employees and their families has piqued the interest of many investors. Best Growth Stock's full report breaks through the noise and offers an extensive comprehensive analysis of Marpai’s current and anticipated financial results, potential catalysts, share structure, cash position, and much more. Access this full analysis free: https://bestgrowthstocks.com/access-mrai-analysis/ (If you cannot click the link above, copy and paste to your browser may be required) Access this full analysis free: https://bestgrowthstocks.com/access-mrai-analysis/ (If you cannot click the link above, copy and paste to your browser may be required) About Marpai, Inc. Marpai, Inc. (Nasdaq: MRAI) is a leading, national TPA company bringing value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Marpai works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Contact Details Best Growth Stocks Steve Macalbry Editor@bestgrowthstocks.com

March 04, 2024 07:59 AM Eastern Standard Time

Image

The New American Home® 2024

News Media Group, Inc.

Contact Details News Media Group, Inc. Karl Wayne +1 334-440-6397 karl@newsmg.com Company Website https://newsmg.com/

March 04, 2024 07:00 AM Eastern Standard Time

Video

All Industries

XRP (XRP), BNB (BNB), and KangaMoon (KANG) Continue Their Stellar Performance With Holder Excitement Increasing - Here’s Why

Forte Minerals Acquires the Alto Ruri Epithermal Gold Prospect Near Barrick’s Pierina Mine in Central Perú

MicroSalt revolutionises salt intake with low sodium technology and big growth plans

Voyageur Pharmaceuticals and API Forge Alliance for Carbon-Based Imaging Drug Advancement

Knightscope (NASDAQ: KSCP) Demonstrates The Value In Its Autonomous Security Robots As Clients Continue To Renew Recurring Revenue Contracts

No More Jitters? Company Says Its Hydro-CaffeineTM Improves Your Morning Caffeine Fix’s Benefits By 400-500%

Enhanced Design Breakthrough Makes Ventripoint's VMS+ Even Simpler to Use

BestGrowthStocks.Com Issues Comprehensive Analysis of Marpai Inc

The New American Home® 2024